Predicting the Immune Response

MHC I. Assays and Complexes

NeoScreen™ Epitope Binding Assays

FcRn. 100% active. Many species available

Predicting the Immune Response with NeoScreen™

Are you searching for Neo-Epitopes?

Our unique NeoScreen™ Assay allows you to identify top neo-epitope candidates.

Tell me more!

It’s all about recognition

Immune recognition starts with MHC I and MHC II.

Learn why you can rely on Immunitrack’s competence in manufacturing immune reagents.

What Immunitrack Does

Our aim is to help our customers predict the immune response. Immunogenicity prediction is a key need in the feld of biologics, particularly for cancer vaccines. We want to help our customers to identify “real” epitopes (those that will cause a T-cell response) from pools of potential neo-epitopes generated by sequencing data.

Conversely (e.g., protein/peptide-based therapeutics), there is often a need to predict if an unwanted immune response can occur.

Watch video

Reagents – Order online!

When you’re investigating the immune response, you need reagents you can rely on.

Immunitrack has an extensive list of the most common MHC/epitope reagents both monomers and tetramers, as well as FcRn. Click on the category of interest to find out more.

Immunitrack proposes also the production of customized MHC I & II reagents as well as MHC binding assays on request. Contact us on info@immunitrack.com to discuss projects.

Order online

Meet Us in Oslo at the Cancer Crosslinks 2020 Event on the 16th January!

January 8, 2020

Assess Neo-Epitope Immunogenicity with NeoScreen® New Year Promotion

October 25, 2019

Sune Justesen to present NeoScreen® Platform at World Vaccine Congress Europe in Barcelona

September 10, 2019

Research collaboration – developing new ways of designing vaccines for flaviviruses such as Zika

Immuno-oncology

Identify neo-epitopes faster.

Vaccines

Identify potent antigens that the patient’s immune system will respond to.

Precision Medicine

Profile patients for adoptive T-cell therapy.

De-immunization

Reduce the immunogenicity of therapeutic proteins. Maintain function and develop best-in-class biologics.

Immunitrack has a stellar reputation in the field of peptide-MHC manufacture. Communication was prompt and clear. Our MHC tetramers arrived within a short timeframe. This allowed us to do faster iterations on our project.

Immunologist Biotech Company, California

Novozymes Biopharma uses the FcRn from Immunitrack to develop the albumin based half-life extension platform Veltis®. We have tested a number of commercially available FcRn’s in our screening assay developed for identification of albumin variants with improved affinity for FcRn receptor and found that the biotinylated FcRn’s from Immunitrack deliver superior performance. These biotinylated FcRn’s enable a robust immobilization to Streptavidin-biosensors (Octet Red96 from Pall ForteBio) and deliver very consistent and robust data.

Birgitte Andersen Science manager, Novozymes

IMMUNITRACK